StockData
Processa Pharmaceuticals, Inc. logo

Processa Pharmaceuticals, Inc. (PCSA) company profile

PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$1.73+0.01 (+0.58%)

Close on Nov 17, 2026Market cap $4.83MP/E –Yield –

About Processa Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies. The company identifies existing, widely used cancer treatments that exhibit high toxicity and treatment-limiting side effects, modifying their metabolism or distribution to improve safety and efficacy while lowering toxicity. Its oncology pipeline includes PCS6422 (NGC-Cap), an oral therapy combined with capecitabine currently evaluated for solid tumors such as advanced breast cancer, and PCS11T (NGC-Iri), an analog targeting solid tumors. In addition to its oncology pipeline, the company evaluates opportunities for non-oncology clinical assets, including PCS12852 for gastroparesis and PCS499 for primary glomerular diseases.

The company conducts clinical and preclinical development programs, including a Phase 2 trial for PCS6422 and preclinical evaluations for PCS11T. Processa Pharmaceuticals maintains corporate offices in Vero Beach, Florida, where its principal executive operations are located.

Summary of the business section of Processa Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Processa Pharmaceuticals, Inc.
Founded
2011
Headquarters
Vero Beach, FL
Address
601 21st Street, Suite 300 32960
Phone
(443) 776-3133
Employees
12, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Cherry Bekaert LLP, Tampa, Florida

Stock & identifiers

Ticker
PCSA
Former tickers
HWX until Nov 20, 2017
Exchange
Nasdaq
IPO date
Mar 7, 2014
Shares outstanding
3M, Aug 7, 2026
Public float
$8.10M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-25 reverse, Dec 17, 2025; 1-for-20 reverse, Jan 22, 2024; 1-for-7 reverse, Dec 23, 2019; 8-for-3, Apr 16, 2018; 1-for-7 reverse, Dec 8, 2017
SEC CIK
1533743
CUSIP
74275C403
ISIN
US74275C4033
FIGI
BBG003MN5ZP8
Share class FIGI
BBG003MN60F5
LEI
529900A51HZIE4XJB960
EIN
45-1539785

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
George K. NgChief Executive Officer, Director21,380
David YoungPres. Research & Development, Director24,412
Gregory J. FlesherChief Operating Officer–
Wendy GuyChief Administrative Officer14,727
Russell SkibstedChief Financial Officer16,689
Patrick LinChief Business - Strategy Off14,853
Sian BigoraChief Development Officer7,748
Sheila GujrathiDirector–
Geraldine PannuDirector2,391
James R. NealDirector1,021
Justin W. YorkeDirector2,099
Khoso BaluchDirector2,528

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$673.30K$565.07K$530.99K$2–
FY2024
George Ng
$521.03K$288.39K$286.24K$13–
FY2024
Peo
$521.03K$288.39K$286.24K$13–
FY2023
David Young
$108.88K-$16.30K$321.70K$100–
FY2023
George Ng
$472.85K$428.85K$321.70K$100–
FY2023
Peo
$472.85K$428.85K$321.70K$100–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
George Ng
Chief Executive Officer
$400.00K$50.00K$50.69K$148.69K$23.93K$673.30K+29%
Russell Skibsted
Chief Financial Officer
$400.00K$55.00K$21.38K$62.73K$27.65K$566.76K+132%
Sian Bigora
Former Chief Development and Regulatory Officer
$367.76K$40.00K$19.01K$55.76K$12.58K$495.10K+51%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 13, 2026, we had 12 full- and part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 29, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 8, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 10, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 6, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 21, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 17, 2020ListingRegistration of securities on an exchange (Form 8-A)
Dec 6, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 16, 2018Late filingNotification of late filing
Apr 2, 2018Late filingNotification of late filing
Mar 30, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 14, 2017Late filingNotification of late filing
Nov 2, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 20, 2017Name changeName changed from Heatwurx, Inc. to Processa Pharmaceuticals, Inc.
Oct 17, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 12, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 31, 2016Late filingNotification of late filing
Nov 16, 2015Late filingNotification of late filing
Sep 22, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 10, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 14, 2015Late filingNotification of late filing
Mar 30, 2015Late filingNotification of late filing
Aug 14, 2014Late filingNotification of late filing

See a number that looks wrong?